EANM position paper on the role of radiobiology in nuclear medicine

Research output: Contribution to journalArticle

Standard

EANM position paper on the role of radiobiology in nuclear medicine. / Aerts, An; Uberlein, Uta; Lassmann, Michael ; Holm, Sören; Hustinx, Roland; Konijnenberg, Mark W.; Strigari, Lidia; van Leeuwen, Fijs W.B.; Glatting, Gerhard.

In: European Journal of Nuclear Medicine and Molecular Imaging , Vol. 237, 29.04.2021, p. 1-13.

Research output: Contribution to journalArticle

Harvard

Aerts, A, Uberlein, U, Lassmann, M, Holm, S, Hustinx, R, Konijnenberg, MW, Strigari, L, van Leeuwen, FWB & Glatting, G 2021, 'EANM position paper on the role of radiobiology in nuclear medicine', European Journal of Nuclear Medicine and Molecular Imaging , vol. 237, pp. 1-13. https://doi.org/10.1007%2Fs00259-021-05345-9

APA

Aerts, A., Uberlein, U., Lassmann, M., Holm, S., Hustinx, R., Konijnenberg, M. W., ... Glatting, G. (2021). EANM position paper on the role of radiobiology in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging , 237, 1-13. https://doi.org/10.1007%2Fs00259-021-05345-9

Vancouver

Aerts A, Uberlein U, Lassmann M, Holm S, Hustinx R, Konijnenberg MW et al. EANM position paper on the role of radiobiology in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging . 2021 Apr 29;237:1-13. https://doi.org/10.1007%2Fs00259-021-05345-9

Author

Aerts, An ; Uberlein, Uta ; Lassmann, Michael ; Holm, Sören ; Hustinx, Roland ; Konijnenberg, Mark W. ; Strigari, Lidia ; van Leeuwen, Fijs W.B. ; Glatting, Gerhard. / EANM position paper on the role of radiobiology in nuclear medicine. In: European Journal of Nuclear Medicine and Molecular Imaging . 2021 ; Vol. 237. pp. 1-13.

Bibtex - Download

@article{336283f2f7aa4e9b896b0951bc0e797c,
title = "EANM position paper on the role of radiobiology in nuclear medicine",
abstract = "With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.",
keywords = "Radiobiology, Dosimetry, Biodosimetry, Biomarkers, Radionuclide therapy",
author = "An Aerts and Uta Uberlein and Michael Lassmann and S{\"o}ren Holm and Roland Hustinx and Konijnenberg, {Mark W.} and Lidia Strigari and {van Leeuwen}, {Fijs W.B.} and Gerhard Glatting",
note = "Score=10",
year = "2021",
month = "4",
day = "29",
doi = "10.1007{\%}2Fs00259-021-05345-9",
language = "English",
volume = "237",
pages = "1--13",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",

}

RIS - Download

TY - JOUR

T1 - EANM position paper on the role of radiobiology in nuclear medicine

AU - Aerts, An

AU - Uberlein, Uta

AU - Lassmann, Michael

AU - Holm, Sören

AU - Hustinx, Roland

AU - Konijnenberg, Mark W.

AU - Strigari, Lidia

AU - van Leeuwen, Fijs W.B.

AU - Glatting, Gerhard

N1 - Score=10

PY - 2021/4/29

Y1 - 2021/4/29

N2 - With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.

AB - With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.

KW - Radiobiology

KW - Dosimetry

KW - Biodosimetry

KW - Biomarkers

KW - Radionuclide therapy

UR - https://ecm.sckcen.be/OTCS/llisapi.dll?func=ll&objId=43602290&objAction=download

U2 - 10.1007%2Fs00259-021-05345-9

DO - 10.1007%2Fs00259-021-05345-9

M3 - Article

VL - 237

SP - 1

EP - 13

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -

ID: 7113188